Clinical trial
Safety Study of the Drug RG1068 in Patients With Obsessive Compulsive Disorder
NCT00216294 · Indiana University School of Medicine, Other · Completed
Key facts
| NCT number | NCT00216294 |
|---|---|
| Title | Safety Study of the Drug RG1068 in Patients With Obsessive Compulsive Disorder |
| Official title | An Open-Label, Dose Escalation, Pilot Study to Assess the Safety and Efficacy of Subcutaneous RG1068 (Synthetic Human Secretin) in Patients With Obsessive Compulsive Disorder (OCD) |
| Lead sponsor | Indiana University School of Medicine, Other |
| Collaborators | Shekhar, Anantha M.D., Ph.D. Repligen Corporation Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Obsessive Compulsive Disorder (OCD) |
| Intervention type | Drug |
| Interventions | RG1068 (Synthetic Human Secretin) |
| Enrollment | 12 |
| Start date | Feb 1, 2005 |
| Primary completion | Apr 1, 2006 |
| Completion | Apr 1, 2006 |
| First posted | Sep 22, 2005 |
| Last update posted | Feb 23, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: